Catalyst
Slingshot members are tracking this event:
AFM13 Phase 2a interim data due 2Q 2016 in Hodgkin lymphoma (HL) for Affimed’s lead candidate
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AFMD |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 06, 2016
Occurred Source:
http://www.affimed.com/pdf/20161206_afmd_pr_ash_posters_final.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Afm13, Phase 2a Interim Data, 2q 2016, Hodgkin Lymphoma, Lead Candidate, Bispecific Cd30/cd16a Nk-cellengaging Tandab
